Cultivation Capital
SlowingSt. Louis, MOBiotech & pharma, Medical devices, Digital healthLast fund filed April 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Cultivation Capital Life Sciences Fund IV | April 2025 | $40M | $6.5M | 0 |
| Cultivation Capital Life Sciences Fund II | October 2016 | $30M | $19M | 54 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David SmollerNot on the current fund | Slowing | Biotech & pharma, AI & machine learning, Healthcare services | 8 | 1 |
| Bobby SandageNot on the current fund | Quiet | Biotech & pharma | 7 | 0 |
| Rick RyanNot on the current fund | Quiet | Biotech & pharma | 3 | 0 |
| Sean Morris | Quiet | Medical devices, Biotech & pharma, Fintech | 7 | 0 |
| William Schmidt | Quiet | Digital health, Medical devices | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of Cultivation Capital’s own portfolio companies, based on 29 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Cultivation Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| HealthX Ventures | 7 | CARDIALEN, Fifth Eye, ImageMoverMD, NarrativeDx, Ra Medical Systems, SentiAR, VedaPointe |
| Lewis & Clark | 3 | Adarza BioSystems, Euphrates Vascular, Pulse Therapeutics |
| Arboretum Ventures | 1 | Fifth Eye |
| Genoa Ventures | 1 | Adarza BioSystems |
A shared board seat: a company where filings name a Cultivation Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.